Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17181448 | 0.89 | PREP (0.36) | PREPCHRM1GRIN2CKDM4ELMNA | |
| SCHEMBL17181465 | 0.79 | CHRM1 (0.44) | CHRM1HRH3KDM4ELMNACYP1A2 | |
| SCHEMBL17192038 | 0.79 | KDM4E (0.43) | PREPKDM4ELMNACYP1A2POLB | |
| SCHEMBL17181557 | 0.77 | TP53 (0.40) | KDM4ELMNACYP1A2POLBCYP3A4 | |
| SCHEMBL15680503 | 0.75 | CHRNA7 (0.39) | PREPCHRM1SMN1; SMN2 | |
| SCHEMBL17181530 | 0.74 | POLB (0.46) | HRH3KDM4ELMNACYP1A2POLB | |
| SCHEMBL15991610 | 0.74 | HRH3 (0.45) | HRH3KDM4ESMN1; SMN2 | |
| SCHEMBL14845160 | 0.73 | PIK3CD (0.42) | PREPCHRM1HRH3KDM4ELMNA | |
| SCHEMBL15991707 | 0.71 | TP53 (0.38) | PREPKDM4ELMNACYP1A2POLB | |
| SCHEMBL14699773 | 0.71 | UGCG (0.41) | CHRM1GRIN2CHRH3KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | PREP 951/4885CHRM1 2403/4885GRIN2C 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.